Akero Therapeutics (AKRO) Competitors $53.80 -0.11 (-0.20%) Closing price 04:00 PM EasternExtended Trading$53.72 -0.08 (-0.16%) As of 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKRO vs. SMMT, ASND, RDY, VTRS, ROIV, BBIO, MRNA, QGEN, ELAN, and VRNAShould you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Moderna (MRNA), QIAGEN (QGEN), Elanco Animal Health (ELAN), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Akero Therapeutics vs. Its Competitors Summit Therapeutics Ascendis Pharma A/S Dr. Reddy's Laboratories Viatris Roivant Sciences BridgeBio Pharma Moderna QIAGEN Elanco Animal Health Verona Pharma PLC American Depositary Share Akero Therapeutics (NASDAQ:AKRO) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends. Does the media favor AKRO or SMMT? In the previous week, Summit Therapeutics had 19 more articles in the media than Akero Therapeutics. MarketBeat recorded 24 mentions for Summit Therapeutics and 5 mentions for Akero Therapeutics. Akero Therapeutics' average media sentiment score of 1.01 beat Summit Therapeutics' score of 0.48 indicating that Akero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akero Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend AKRO or SMMT? Akero Therapeutics presently has a consensus target price of $73.38, indicating a potential upside of 36.38%. Summit Therapeutics has a consensus target price of $31.14, indicating a potential upside of 66.18%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 1 Sell rating(s) 7 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.31Summit Therapeutics 4 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.50 Is AKRO or SMMT more profitable? Akero Therapeutics' return on equity of -15.84% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -15.84% -14.59% Summit Therapeutics N/A -278.57%-241.80% Do institutionals and insiders believe in AKRO or SMMT? 4.6% of Summit Therapeutics shares are owned by institutional investors. 7.1% of Akero Therapeutics shares are owned by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation & earnings, AKRO or SMMT? Summit Therapeutics has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$252.06M-$2.00-26.90Summit Therapeutics$700K19,887.16-$221.32M-$1.01-18.55 Which has more risk & volatility, AKRO or SMMT? Akero Therapeutics has a beta of -0.29, indicating that its stock price is 129% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.13, indicating that its stock price is 213% less volatile than the S&P 500. SummarySummit Therapeutics beats Akero Therapeutics on 11 of the 15 factors compared between the two stocks. Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKRO vs. The Competition Export to ExcelMetricAkero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.31B$3.48B$6.22B$10.69BDividend YieldN/A2.27%5.72%4.87%P/E Ratio-26.9023.0629.1427.22Price / SalesN/A476.60577.13128.70Price / CashN/A47.5937.5161.65Price / Book5.0010.6612.476.59Net Income-$252.06M-$52.56M$3.32B$276.14M7 Day Performance-0.02%4.97%1.87%0.02%1 Month Performance18.97%16.48%8.40%3.60%1 Year Performance74.11%14.95%63.49%32.76% Akero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKROAkero Therapeutics3.7605 of 5 stars$53.80-0.2%$73.38+36.4%+72.6%$4.31BN/A-26.9030SMMTSummit Therapeutics3.0335 of 5 stars$22.93+7.4%$31.29+36.4%-5.6%$15.86B$700K-22.70110Trending NewsEarnings ReportAnalyst ForecastOptions VolumeASNDAscendis Pharma A/S3.0334 of 5 stars$208.43-0.5%$248.29+19.1%+58.0%$12.93B$393.54M-40.391,017News CoverageAnalyst UpgradeGap UpRDYDr. Reddy's Laboratories2.4528 of 5 stars$14.36+0.1%$16.95+18.1%-7.5%$11.97B$3.81B21.7527,811Positive NewsVTRSViatris3.5019 of 5 stars$9.86+1.2%$10.40+5.5%-12.3%$11.36B$14.74B-3.4032,000ROIVRoivant Sciences2.7102 of 5 stars$16.21+1.1%$19.94+23.0%+48.8%$10.95B$29.05M-23.16860BBIOBridgeBio Pharma4.6007 of 5 stars$55.96+0.8%$63.94+14.3%+116.2%$10.61B$221.90M-13.68400Analyst ForecastMRNAModerna4.2962 of 5 stars$26.74-0.3%$41.81+56.4%-49.6%$10.48B$3.24B-3.555,800Trending NewsAnalyst ForecastQGENQIAGEN4.1848 of 5 stars$47.30+1.0%$49.40+4.4%+16.5%$10.41B$1.98B27.955,765Positive NewsELANElanco Animal Health2.7355 of 5 stars$20.04+1.4%$19.14-4.5%+67.7%$9.82B$4.44B23.309,000Analyst ForecastVRNAVerona Pharma PLC American Depositary Share1.568 of 5 stars$106.91flat$109.00+2.0%N/A$9.21B$42.28M-107.9930Positive News Related Companies and Tools Related Companies Summit Therapeutics Alternatives Ascendis Pharma A/S Alternatives Dr. Reddy's Laboratories Alternatives Viatris Alternatives Roivant Sciences Alternatives BridgeBio Pharma Alternatives Moderna Alternatives QIAGEN Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKRO) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKRO Stock Alerts